SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC — Stella

Recruiting

Back to Radiation Therapy trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

Trial locations(1 site)

China

Peking University First Hospital, Beijing, Beijing Municipality

Key details

Phase

Safety & dosing

Sponsor

Peking University First Hospital

Enrollment target

~30 participants

Started

January 2019

Primary completion

February 2027

Age range

18 Years – 80 Years

Last updated March 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov